RPRX - Royalty Pharma Plc

RPRX - Royalty Pharma Plc

https://www.royaltypharma.com

Recent News

Powered by Alpha Vantage

Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation - Royalty Pharma ( NASDAQ:RPRX )

Benzinga • 4 days, 4 hours ago • score: 0.28

On track to deliver Portfolio Receipts of $4.7 billion or more by 2030, significantly ahead of consensus Goal to achieve at least mid-teens average annual total shareholder return over next 5 years with significant upside potential from recognition for Royalty Pharma's platform value

Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

GlobeNewswire • 1 week, 3 days ago • score: 0.24

NEW YORK, Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:20 p.m. ET.

Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes

GlobeNewswire • 1 week, 5 days ago • score: 0.10

NEW YORK, Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following ( collectively, the "Notes" ...

Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million

GlobeNewswire • 3 weeks ago • score: 0.22

NEW YORK, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it has acquired a royalty interest in Amgen's Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager ( BiTE ) , from BeOne Medicines for $885 million upfront.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.

52W High

$37.97

52W Low

$23.59

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.57

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

15.75

Forward P/E (<15 better)

10.42

EV/EBITDA (<8 favorable)

11.44

EV/Revenue (<3 favorable)

9.59

P/S (TTM) (<3 favorable)

9.12

P/B (<3 favorable)

2.46

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

8.74%

Institutions (25–75% balanced)

82.41%

Shares Outstanding

432,293,000

Float

379,852,000

Dividend Yield (2–6% sweet spot)

0.02%

Ex‑Dividend Date

2025-08-15

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

2,305,243,000

Gross Profit (TTM)

2,699,889,000

EPS (TTM)

2.29

Profit Margin (>10% good)

0.44%

Operating Margin (TTM) (higher better)

0.39%

ROE (TTM) (>15% strong)

0.17%

EPS YoY (Quarterly) (>10% good)

-0.69

Revenue YoY (Quarterly) (>8% good)

0.08

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—